Investor Presentaiton
63
Investor presentation
Full year 2022
Patient access to anti-obesity medications is improving in both
the US and IO
The 40 million people having access to WegovyⓇ is nearly the number
of people with diabetes in the US (~50 million)
Restricted reimbursement for SaxendaⓇ is progressing
EXAMPLES
~110m
Obesity prevalence in US adults¹
~60m
Commercial Channel
~80% formulary access
• ~50% of employers opt-in
~30m
People with
commercial coverage
~10m
Medicaid²
BMI > 30
with one co-morbidity
BMI > 35
With pre-diabetes and risk of CV
(+)
~60% coverage by private insurance, 20% of
which includes restricted/unrestricted coverage
SaxendaⓇ reimbursed in April 2020 in selected
patient groups
Note: Obesity is defined as BMI > 30.
1 Prevalence: Adult obesity facts. Centers for Disease Control and Prevention, https://www.cdc.gov/obesity/data/adult.html; US Census Bureau. QuickFacts: United States. https://www.census.gov/quickfacts/fact/table/US#viewtop. Accessed Mar, 2021.;
2 Also includes DoD and government employees
Novo NordiskⓇView entire presentation